$OKYO News

OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May

OKYO Pharma to hold Scientific Advisory Board meeting at ASCRS 2026

OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting

OKYO Pharma Announces Chairman and Founder Acquires Shares

OKYO Pharma Announces Director Acquires Shares

OKYO Pharma's Panetta Partners Buys 10,119 Shares At An Average Price Of $1.59, Raising Executive Chairman Gabriele Cerrone's Total Holdings To 10,526,416 Shares

OKYO Pharma Announces Chief Development Officer and Director Acquires Shares

OKYO Pharma Director John Brancaccio Buys 5,000 Shares At An Average Price Of $1.61, Raising Total Holdings to 31,201

OKYO Pharma Executive Buys More Shares, Signals Confidence

OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial

OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain

OKYO Pharma Reports Trial Results For Eye Pain Treatment

OKYO Pharma to present first-in-human urcosimod data at ARVO 2026

OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress

This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Friday

Piper Sandler Initiates Coverage On OKYO Pharma with Overweight Rating, Announces Price Target of $7

OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain

OKYO Pharma prices $20M offering to fund late-stage eye drug trial

Reported Earlier, OKYO Pharma Prices $20M Underwritten Public Offering Of 10,815,000 Ordinary Shares At $1.85 Per Share

Reported Earlier, OKYO Pharma Prices $20M Underwritten Public Offering Of 10,815,000 Ordinary Shares At $1.85 Per Share